• Je něco špatně v tomto záznamu ?

Patients with oral tongue squamous cell carcinoma and co‐existing diabetes exhibit lower recurrence rates and improved survival: Implications for treatment

AM. Salehi, L. Wang, X. Gu, PJ. Coates, L. Norberg Spaak, N. Sgaramella, K. Nylander

. 2024 ; 27 (4) : 142. [pub] 20240206

Status neindexováno Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24005517

Locoregional recurrences and distant metastases are major problems for patients with squamous cell carcinoma of the head and neck (SCCHN). Because SCCHN is a heterogeneous group of tumours with varying characteristics, the present study concentrated on the subgroup of squamous cell carcinoma of the oral tongue (SCCOT) to investigate the use of machine learning approaches to predict the risk of recurrence from routine clinical data available at diagnosis. The approach also identified the most important parameters that identify and classify recurrence risk. A total of 66 patients with SCCOT were included. Clinical data available at diagnosis were analysed using statistical analysis and machine learning approaches. Tumour recurrence was associated with T stage (P=0.001), radiological neck metastasis (P=0.010) and diabetes (P=0.003). A machine learning model based on the random forest algorithm and with attendant explainability was used. Whilst patients with diabetes were overrepresented in the SCCOT cohort, diabetics had lower recurrence rates (P=0.015 after adjusting for age and other clinical features) and an improved 2-year survival (P=0.025) compared with non-diabetics. Clinical, radiological and histological data available at diagnosis were used to establish a prognostic model for patients with SCCOT. Using machine learning to predict recurrence produced a classification model with 71.2% accuracy. Notably, one of the findings of the feature importance rankings of the model was that diabetics exhibited less recurrence and improved survival compared with non-diabetics, even after accounting for the independent prognostic variables of tumour size and patient age at diagnosis. These data imply that the therapeutic manipulation of glucose levels used to treat diabetes may be useful for patients with SCCOT regardless of their diabetic status. Further studies are warranted to investigate the impact of diabetes in other SCCHN subtypes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24005517
003      
CZ-PrNML
005      
20240412130953.0
007      
ta
008      
240405s2024 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/ol.2024.14275 $2 doi
035    __
$a (PubMed)38385115
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Salehi, Amir M $u Department of Medical Biosciences/Pathology, Umeå University, SE 901 85 Umeå, Sweden
245    10
$a Patients with oral tongue squamous cell carcinoma and co‐existing diabetes exhibit lower recurrence rates and improved survival: Implications for treatment / $c AM. Salehi, L. Wang, X. Gu, PJ. Coates, L. Norberg Spaak, N. Sgaramella, K. Nylander
520    9_
$a Locoregional recurrences and distant metastases are major problems for patients with squamous cell carcinoma of the head and neck (SCCHN). Because SCCHN is a heterogeneous group of tumours with varying characteristics, the present study concentrated on the subgroup of squamous cell carcinoma of the oral tongue (SCCOT) to investigate the use of machine learning approaches to predict the risk of recurrence from routine clinical data available at diagnosis. The approach also identified the most important parameters that identify and classify recurrence risk. A total of 66 patients with SCCOT were included. Clinical data available at diagnosis were analysed using statistical analysis and machine learning approaches. Tumour recurrence was associated with T stage (P=0.001), radiological neck metastasis (P=0.010) and diabetes (P=0.003). A machine learning model based on the random forest algorithm and with attendant explainability was used. Whilst patients with diabetes were overrepresented in the SCCOT cohort, diabetics had lower recurrence rates (P=0.015 after adjusting for age and other clinical features) and an improved 2-year survival (P=0.025) compared with non-diabetics. Clinical, radiological and histological data available at diagnosis were used to establish a prognostic model for patients with SCCOT. Using machine learning to predict recurrence produced a classification model with 71.2% accuracy. Notably, one of the findings of the feature importance rankings of the model was that diabetics exhibited less recurrence and improved survival compared with non-diabetics, even after accounting for the independent prognostic variables of tumour size and patient age at diagnosis. These data imply that the therapeutic manipulation of glucose levels used to treat diabetes may be useful for patients with SCCOT regardless of their diabetic status. Further studies are warranted to investigate the impact of diabetes in other SCCHN subtypes.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Wang, Lixiao $u Department of Medical Biosciences/Pathology, Umeå University, SE 901 85 Umeå, Sweden
700    1_
$a Gu, Xiaolian $u Department of Medical Biosciences/Pathology, Umeå University, SE 901 85 Umeå, Sweden
700    1_
$a Coates, Philip J $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno 656 53, Czech Republic
700    1_
$a Norberg Spaak, Lena $u Department of Medical Biosciences/Pathology, Umeå University, SE 901 85 Umeå, Sweden
700    1_
$a Sgaramella, Nicola $u Department of Medical Biosciences/Pathology, Umeå University, SE 901 85 Umeå, Sweden $u Department of Oral and Maxillo-Facial Surgery, Mater Dei Hospital, I-70125 Bari, Italy
700    1_
$a Nylander, Karin $u Department of Medical Biosciences/Pathology, Umeå University, SE 901 85 Umeå, Sweden
773    0_
$w MED00193499 $t Oncology letters $x 1792-1082 $g Roč. 27, č. 4 (2024), s. 142
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38385115 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240405 $b ABA008
991    __
$a 20240412130945 $b ABA008
999    __
$a ok $b bmc $g 2075941 $s 1215279
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 27 $c 4 $d 142 $e 20240206 $i 1792-1082 $m Oncology letters $n Oncol Lett $x MED00193499
LZP    __
$a Pubmed-20240405

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...